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n Abstract: Inflammatory breast cancer (IBC) is a relatively rare and extremely aggressive form of breast cancer that is
diagnosed clinically. Standardization of clinical diagnoses is challenging, both nationally and internationally; moreover, IBC
coding definitions used by registries have changed over time. This study aimed to compare diagnostic factors of IBC
reported in a U.S. Surveillance, Epidemiology, and End Results (SEER) registry to clinical criteria found in the medical
records of all invasive breast cancer cases at a single institution. We conducted a medical record review of all female inva-
sive breast cancers (n = 915) seen at an NCI-designated comprehensive cancer center in Detroit from 2007 to 2009. IBC
cases were identified based on the presence of the main clinical characteristics of the disease (erythema, edema, peau
d’orange). We compared the proportion of IBC out of all breast cancers, using these clinical criteria and the standard SEER
IBC codes. In the reviewed cases, the clinical criteria identified significantly more IBC cases (n = 74, 8.1%) than the stan-
dard IBC SEER definition (n = 19, 2.1%; p < 0.0001). No IBC cases were identified in the cancer center records using the
SEER pathologic coding, which requires the diagnosis of inflammatory carcinoma on the pathology report, a notation that is
rarely made. Emphasis must be placed on the documentation of clinical and pathologic characteristics of IBC in the medical
record, so that analysis of putative IBC subtypes will be possible. Our results indicate the need for a consensus on the defi-
nition of IBC to be utilized in future research. n
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Inflammatory breast cancer (IBC) is the most aggres-sive and deadly form of breast cancer (1), with
nearly twice the risk of death as compared to locally
advanced breast cancer (2,3). Despite its name, IBC is
not observed to be associated with a profuse cellular
inflammatory response at the time of diagnosis. In
fact, the characteristic redness and swelling of
the breast in IBC that in many cases may resemble
inflammation are due to lymphatic channels in the
dermis being clogged by tumor cells, a process termed
dermal lymphatic invasion (DLI) by tumor emboli
(4,5). Currently, a clinical IBC diagnosis is made when
the history and physical examination document the
rapid onset (weeks to months) of the characteristic
skin features and a biopsy of the breast shows carci-
noma (6–8). However, the main clinical symptoms
(erythema, edema, and peau d’orange) and pathologic
characteristics (DLI) of IBC are not uniformly
observed among patients with IBC. Therefore, in prac-
tice, by using a combination of clinical and pathologic
criteria, IBC cases can be identified in different ways
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for different patients (9). The use of differing criteria
for IBC diagnosis—and the relative rarity of the disease—
has hampered epidemiologic research on IBC, making
it difficult to obtain adequate representative samples of
IBC cases and to compare results across studies.
The documentation of IBC in the Surveillance, Epi-
demiology, and End Results (SEER) registry data has
varied over time. Historically, IBC cases were assigned
according to the pathologic codes (International Classi-
fication of Diseases for Oncology [ICD-O code 8530])
(10) specifically reserved for IBC with DLI. However,
a rule implemented in 2007 states that the ICD-O his-
tology code 8530 for IBC should only be used “when
the final diagnosis of the pathology report specifically
states inflammatory carcinoma” (11). Beginning in
2004, the American Joint Cancer Committee (AJCC)
Stage “T4d” variable has been designated by SEER to
describe IBC as “a clinicopathologic entity character-
ized by diffuse erythema and edema (peau d’orange) of
the breast, often without an underlying mass involving
the majority of the breast” (12). More recently, IBC
cases have been identified in the SEER registry using
either the AJCC T4d variable or the extent of disease
(EOD) variables, which record a combined clinical and
pathologic assessment of disease abstracted from the
pathology report (9). A detailed report of the EOD
codes 600, 710, 715, 720, 725, 730, 750, and 780 for
assigning possible IBC cases are described in a SEER
report of 2009 (13). A standard IBC definition of
either AJCC T4d or EOD 710-730 or pathologic ICD-
O 8530 has recently been advocated to identify IBC
cases from the SEER registries (14,15).
The ensuing complexities of registry coding of
IBC, which stems from IBC’s unique and unusual
presentation, makes comparing incidence of IBC
between countries challenging. Furthermore, there
does appear to be a heterogeneous global distribution
in IBC occurrence. Based on SEER data, between
1% and 6% of all patients with breast cancer in the
United States have IBC (16–18). However, in Tuni-
sia, up to 55% of breast cancer cases have been
reported as IBC (19), while more recent estimates
describe IBC in Tunisia as 5–7% of breast cancer
cases (20). Using a simplified clinical IBC definition
of erythema, edema, and peau d’orange as its three
main clinical features: most likely IBC exhibited all
three features, possible IBC cases had any two of the
three signs or had peau d’orange only, and non-IBC
cases had edema only, erythema only, or none of
these three clinical features (7,8), a population-based
study demonstrated that 11% of all breast cancers in
Egypt are likely IBC, which is unequivocally higher
than what is currently reported in the U.S. (21).
Regional variations in IBC may reflect differences in
diagnostic tools, disease definition, or true differences
in occurrence due to varying levels of risk factors by
region. Identical criteria for the identification of IBC
cases would greatly facilitate comparative studies.
The specific aim of this study was to ascertain the
number of IBC cases at a single institution in
Detroit, Michigan for a 3-year period (2007–2009)
using clinical criteria to identify IBC cases. By apply-
ing an identical case ascertainment system as was
used in Egypt to medical records in the United
States, we establish a means for comparisons between
the burden of IBC relative to total breast cancer in
Egypt and the United States. (21,22). Furthermore,
we compared the IBC cases identified by the clinical
criteria to what is documented in the SEER registry
to determine whether IBC is being ascertained at
equivalent levels using SEER case definitions at a
major comprehensive cancer hospital, which provides
cases to the Detroit SEER registry.
MATERIALS AND METHODS
We conducted a medical record review of all
female invasive breast cancer cases over 20 years of
age seen at an NCI-designated comprehensive cancer
center in Detroit, Michigan from 2007 to 2009. The
center is a tertiary cancer center dedicated to oncol-
ogy care and research. Patients are often referred to
the tertiary facility for surgery, consultations with
specialists, and for short- and long-term patient care.
As is true of all tertiary care centers in the United
States, it is assumed that this center’s patient popula-
tion experiences a greater than average complexity of
disease. This site was chosen due to the large patient
volume, the availability of clinical resources, includ-
ing electronic medical records, catchment within a
SEER registry, and existing collaborations that facili-
tated coordination of the medical record review.
Patients were eligible for the study if they had
received all or part of their breast cancer diagnosis
and/or treatment at the center. We excluded one
patient who was seen only for part of her diagnostic
tests, 34 patients who were treated for a recurrence
or persistence of disease, and 12 patients where this
information was missing. These patients were
excluded out of concern that adequate information
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would not be documented in the medical record. The
final sample for our record review comprised 915
invasive breast cancer cases.
For eligible cases, information was extracted from
the records regarding clinical and pathologic charac-
teristics of the disease at diagnosis. Age, menopausal
status, weight, height, tumor molecular characteristics
(estrogen receptor [ER], progesterone receptor [PR],
human epidermal growth factor receptor 2 [Her2]
expression), imaging, and treatment were recorded.
Tumor size measurements were extracted from clinical
reports based on the size of the palpable mass when
information was available. We identified IBC cases
according to the documentation of the main clinical
characteristics of IBC in the record; erythema (red-
ness), edema (swelling), and peau d’orange (dimpling).
We then compared differences in the number of IBC
cases identified by the clinical criteria (possible and
most likely IBC) with the pathologic (ICD-O 8530)
and the standard SEER criteria (ICD-O 8530 or EOD
710-730 or AJCC 6th edition staging T4d). Further,
to be more certain that the cases being identified by
the clinical criteria were truly IBC, we calculated the
number of IBC cases based on a more stringent crite-
rion of clinical IBC as well as treatment with neo-
adjuvant chemotherapy, this being a hallmark of IBC
(but not exclusive to IBC).
Next, we tested whether there were statistically sig-
nificant differences in the proportion of IBC cases
identified using the standard SEER coding systems and
the clinical criteria, using the McNemar’s test. This
nonparametric test accounts for the correlated nature
of our sample by determining whether the marginal
proportions differed between groups. Differences in
characteristics between IBC and non-IBC cases, and in
the presence of clinical symptoms of IBC within cate-
gories of clinical diagnosis, were examined using Chi-
squared tests and Fisher’s exact test for categorical
data and t-tests for continuous variables. Further, we
utilized Chi-squared tests, t-tests, and logistic regres-
sion models to assess tumor characteristics associated
with pathologic evidence of disease (DLI). An alpha
level of 0.05 was used to determine significance, and
all test statistics were two-sided. An EpiInfo v3.5.3
database was used to record information from the
medical records. Statistical analysis was conducted in
both the EpiInfo and SAS (version 9; SAS Institute,
Cary, NC) platforms. Institutional Review Board
approval was obtained from Wayne State University
and the University of Michigan.
RESULTS
Of the 915 breast cancer cases reviewed, the clini-
cal diagnostic criteria identified significantly more IBC
cases (n = 74, 8.1%) than the standard SEER defini-
tion (n = 19, 2.1%; p < 0.001; Table 1). Using the
more stringent criteria to define likely IBC as cases
treated with neo-adjuvant chemotherapy and docu-
menting the clinical characteristics of disease, 5.5% of
all breast cancers would be considered IBC (Table 1).
The SEER pathologic criteria, which are dependent on
the diagnosis of inflammatory carcinoma being explic-
itly stated on the pathology report (presumably due to
findings of DLI), did not identify any cases of IBC
(Table 1). Of the 19 IBC cases identified by the stan-
dard SEER criteria, 15 (79%) were also identified as
IBC by the clinical criteria. However, only 15
(20.3%) of the 74 IBC cases identified by the clinical
criteria were also identified as IBC by the standard
SEER definition.
According to both the clinical and standard SEER
IBC diagnostic criteria, IBC cases were likely to have
a larger mean tumor size, and be Her2 positive as
compared to non-IBC cases (Table 2). IBC cases were
more likely to have DLI noted in the record as com-
pared to non-IBC cases, though this difference was
Table 1. Comparison of different criteria and
SEER coding for the identification of IBC cases
out of 915 invasive breast cancer cases from
2007 to 2009
IBC criteria IBC Count % IBC
Main IBC criteria
Clinical 74 8.1%
Standard 19 2.1%
IBC SEER coding
AJCC T4d 19 2.1%
EOD-E 600 0 0.0%
EOD-E 710 10 1.1%
EOD-E 715 0 0.0%
EOD-E 720 0 0.0%
EOD-E 725 1 0.1%
EOD-E 730 7 0.8%
EOD-E 750 1 0.1%
EOD-E 780 0 0.0%
Histology 8530 0 0.0%
Other IBC criteria
Clinical + Neo-adjuvant Chemo 50 5.5%
Standard + clinical criteria 15 1.6%
Standard only 4 0.4%
Pathologic only 0 0.0%
Clinical = Any two signs of erythema, edema, peau d’orange or peau d’orange alone.
Standard = ICD-O 8530 or EOD-E 710-730 or AJCC 6th edition T4d.
Clinical + Neo-adjuvant = Any two signs of erythema, edema, peau d’orange or peau
d’orange alone AND received neo-adjuvant chemotherapy.
Pathologic = ICD-O 8530.
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not statistically significant for cases defined according
to the clinical criteria (Table 2).
The clinical criteria specified eight cases (0.9%)
that were most likely IBC as they presented all three
characteristics (erythema, edema, peau d’orange). DLI
was documented for 12.5% of the “Most likely IBC,”
3% of the “Possible IBC,” and 1.4% of the “Not
IBC” according to the clinical criteria (p = 0.03;
Table 3). Cases with DLI noted in the record had lar-
ger mean tumor size, were more likely to present with
erythema, edema, angiolymphatic invasion, and ulcer-
ations, and were more likely to be ER and PR nega-
tive as compared to cases without DLI (Tables 4 and
5).
DISCUSSION
Utilizing only the clinical criteria at a comprehen-
sive cancer center in Detroit, Michigan from 2007 to
2009, we found that 8.1% of breast cancers were
IBC. These results suggest for the first time, that the
incidence of IBC is likely to be significantly underesti-
mated in the United States. It is important to keep in
mind that our results are based on a hospital record
review at a tertiary cancer center and not a popula-
tion-based sample. Women who received care at the
cancer center were more likely to have aggressive dis-
ease, with more severe prognoses and therefore would
have been more readily referred to a tertiary facility;
for all these reasons, this hospital-based group would
exhibit higher stage at diagnosis when compared to
the rest of the metropolitan Detroit area (data not
shown). Thus, while we found the proportion of IBC
out of all breast cancers to be higher at this compre-
hensive cancer center, this may not be true in a US
population-based sample. Furthermore, comparing
population-based incidence rates would be the pre-
ferred method to compare IBC occurrence between
Table 2. Descriptive statistics of invasive female breast cancer cases (n = 915) from medical records
diagnosed from 2007 to 2009 at a single institution
All (n = 915)
Clinical IBC
p
Standard IBC
pIBC (n = 74) Non-IBC (n = 841) IBC (n = 19) Non-IBC (n = 896)
Mean age (years) 57.4 57.2 57.4 0.92 59.0 57.4 0.60
Mean tumor size (cm) 3.2 6.2 2.9 < 0.001 8.4 3.1 < 0.001
IBC mentioned (%) 3.4 35.1 0.6 < 0.001 84.2 1.7 < 0.001
Derm lymph inv (%) 1.6 4.1 1.4 0.11 15.8 1.3 < 0.001
ER
ER positive (%) 64.8 59.5 65.3 0.19 57.9 65.0 0.60
ER negative (%) 33.1 40.5 32.5 42.1 32.9
Unknown (%) 2.1 0.0 2.3 0.0 2.1
PR
PR positive (%) 55.1 56.8 54.9 0.41 63.2 54.9 0.67
PR negative (%) 42.7 43.2 42.7 36.8 42.9
Unknown (%) 2.2 0.0 2.4 0.0 2.2
Her2
Her2 positive (%) 16.9 23 16.4 0.04 47.4 16.3 < 0.001
Her2 negative (%) 77.6 77 77.6 47.4 78.2
Unknown (%) 5.5 0 6.0 5.2 5.5
Menopausal status
Pre-menopausal (%) 24.2 31.1 23.5 0.19 21.1 24.2 0.38
Peri-menopausal (%) 6.4 4.1 6.7 0.0 6.6
Postmenopausal (%) 63.9 63.5 64.0 78.9 63.6
Unknown (%) 5.5 1.4 5.8 0.0 5.6
Anthropometrics
Mean Weight in lbs 177.6 184.1 177.0 0.21 185.7 177.4 0.55
Mean Height in ft′in″ 5′5″ 5′3″ 5′5″ 0.68 5′3″ 5′5″ 0.77
Race/Ethnicity
Caucasian (%) 34.6 27.0 35.3 0.54 15.8 35.0 0.43
African-American (%) 55.0 62.2 54.3 73.7 54.7
Hispanic (%) 1.3 1.4 1.3 0.0 1.3
Other (%) 8.1 9.5 8.0 10.5 8.0
Not mentioned (%) 1.0 0.0 1.1 0.0 1.0
Standard IBC = (ICD-O 8530 or EOD-E 710-730 or AJCC T4d), Clinical IBC = any two signs of erythema, edema, peau d’orange or peau d’orange alone.
p-values for differences between IBC and non-IBC for both criteria based on Chi-squared test (or Fisher’s exact test for cell counts <5) for categorical variables and t-tests for continuous
variables.
Sample size: mean age (n = 915), mean tumor size (n = 814), mean weight (n = 887), mean height (n = 880).
188 • hirko ET AL.
countries; however, incidence rates could not be calcu-
lated based on our study design. Finally, our ability to
apply the clinical criteria for IBC case identification is
predicated on the quality of the medical records. If the
quality of the medical records varies significantly
between countries, we will still be limited in our abil-
ity to draw conclusions on global differences in IBC
occurrence. However, hospital medical records are
typically considered accurate and adequate for use in
epidemiologic research of this kind, and the clinical
diagnostic criteria used in this study have been suc-
cessfully applied to medical records in a previous
study (21). To our knowledge, this is the first study to
utilize the precise IBC clinical criteria used in our pre-
vious work in Egypt to calculate the proportion of
IBC out of all breast cancers at a cancer center in the
United States. The study was not designed to validate
the clinical criteria or advocate for the clinical defini-
tion of IBC; rather, it allowed us to use an identical
system to ascertain IBC cases in global comparative
analyses. There is a wide variation in the symptom
presentation of IBC, and most of the clinical charac-
teristics associated with IBC are nonspecific (23). In
our study, due to this nonspecificity of the clinical
characteristics of IBC, cases appearing to be locally
advanced breast cancers may have been identified as
IBC. Therefore, relying on a clinical diagnosis of IBC
can lead to a wide variability in reporting and pre-
sents serious challenges for researchers (17).
While our review did identify 1.6% of cases with
mention of DLI, no cases were coded as pathologic
ICD-O 8530, probably because they did not specifi-
cally mention IBC on the pathology report. The
importance of DLI in IBC diagnosis remains contro-
versial. Some experts prefer a pathologic definition of
IBC inferring that DLI is required for IBC diagnosis
(24,25). There is also a suggestion that pathologic
confirmation of DLI could represent EOD, with cases
diagnosed earlier having less DLI (26). However,
when utilizing cancer registry data, reliance on DLI
for diagnosis may lead to profound underestimation
of IBC incidence (27).
In our study sample, tumor characteristics differed
between cases with and without DLI, suggesting
Table 3. Characteristics of all breast cancer
cases (n = 915) by categories of IBC clinical
criteria
Signs
Most
likely
IBC
Possible
IBC Not IBC p
Total number of cases (%) 8 (0.9) 66 (7.2) 841 (91.9) –
Erythema (%) 8 (100) 27 (40.9) 26 (3.1) < 0.001
Edema (%) 8 (100) 30 (45.5) 20 (2.4) < 0.001
Peau d’orange (%) 8 (100) 46 (69.7) 0 (0.0) < 0.001
Angiolymphatic invasion (%) 2 (25.0) 17 (12.5) 105 (25.8) 0.01
Ulcerations (%) 1 (12.5) 10 (15.2) 24 (2.9) < 0.001
Palpable mass (%) 6 (75.0) 64 (97.0) 758 (90.2) 0.06
Diffuse enlargement (%) 5 (62.5) 20 (30.3) 23 (2.7) < 0.001
Bruising (%) 0 (00.0) 2 (3.0) 12 (1.4) 0.56
Warmth (%) 0 (00.0) 2 (3.0) 0 (0.0) < 0.001
Nipple retraction (%) 2 (25.0) 13 (19.7) 46 (5.5) < 0.001
Dermal lymphatic invasion (%) 1 (12.5) 2 (3.0) 12 (1.4) 0.03
p-value for difference (Chi-squared or Fisher’s exact test with cell counts<5).
Most likely IBC= all three main clinical characteristics noted as present (erythema,
edema, peau d’orange).
Possible IBC = any two main clinical characteristics or peau d’orange only noted as
present.
Not IBC = erythema only, edema only, or no clinical characteristics noted as present.
Table 4. Characteristics of breast tumors with
and without dermal lymphatic invasion (DLI)
DLI (n = 15) No DLI (n = 900) p-value
Mean age (years) 58.1 57.4 0.8
Mean tumor size (cm) 3.9 1.4 0.003
Erythema (%) 26.7 6.3 0.014
Edema (%) 26.7 6.0 0.011
Peau d’orange (%) 6.7 6.1 0.6
Angiolymphatic invasion (%) 60.0 12.8 <0.001
Ulcerations (%) 33.3 3.3 <0.001
Palpable mass (%) 86.7 90.7 0.42
Diffuse enlargement (%) 6.7 5.2 0.56
Bruising (%) 0.0 1.6 0.80
Warmth (%) 0.0 0.2 0.97
Nipple retraction (%) 6.7 6.7 0.65
IBC mentioned (%) 26.7 3.0 0.001
ER
ER positive (%) 26.7 65.4 0.004
ER negative (%) 73.3 32.4
ER missing (%) 0.0 2.1
PR
PR positive (%) 20 55.7 0.013
PR negative (%) 80 42.1
PR missing (%) 0 2.2
Her2
Her2 positive (%) 33.3 16.7 0.17
Her2 negative (%) 66.7 77.8
Unknown (%) 0.0 5.6
Menopausal status
Premenopausal (%) 21.4 24.2 0.66
Perimenopausal (%) 14.3 6.3
Postmenopausal (%) 57.1 64.2
Unknown (%) 7.1 5.2
Race/ethnicity
Caucasian (%) 50 34.6 0.66
African-American (%) 50 55.4
Hispanic (%) 0 1.3
Other (%) 0 8.3
Not mentioned (%) 0 0.3
Anthropometrics
Mean weight in lbs 174.0 178.6 0.74
Mean height in ft′in″ 5′4″ 5′5″ 0.92
p-values for differences between DLI and non-DLI based on Chi-squared test (or Fisher’s
exact test for cell counts <5) for categorical variables and t-tests for continuous variables.
Sample size: mean age (n = 915), mean tumor size (n = 814), mean weight (n = 888),
mean height (n = 880).
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potential etiologic subtypes of IBC based on the pres-
ence of DLI. A study of prognostic factors in IBC
found no prognostic value for the diagnostic selection
group (clinical or pathologic definition), suggesting
that either definition is justified to diagnose IBC (28).
However, in a systematic review, Kim et al. found that
the main cause of differences in treatment outcomes
was the criteria used across studies to identify IBC
(29). Furthermore, SEER data suggest that patients
with clinical but no pathologic features of IBC have a
better prognosis than those with pathologic evidence
of IBC (16); in other words, the manner in which IBC
is classified at the time of diagnosis has implications
for treatment and prognosis. Therefore, it is imperative
that pathologic evidence of disease continue to be
documented explicitly in the pathology reports at
diagnosis along with reference to IBC if suspected, so
that potential subtypes of IBC based on the presence
or absence of DLI can be further investigated.
We conclude that relying on varying systems of
IBC identification to compare incidence across regions
should be avoided. Inclusion of the clinical criteria in
identifying IBC from medical records will increase the
detection of IBC cases, which may lead to improved
patient care. Given the current SEER codification
rules, this study demonstrates that our ability to iden-
tify IBC through the explicit diagnosis being written
on the pathology report is very close to zero. Empha-
sis must be placed on the documentation of clinical
and pathologic characteristics of IBC in the medical
record, so that analysis of putative IBC subtypes will
be possible and we can further evaluate and come to a
consensus on the definition of IBC to be utilized in
future research. The findings of this study add to our
understanding of the global variation in IBC incidence
and have important implications for diagnosis, treat-
ment, prognosis, and future research on IBC.
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